Your session is about to expire
← Back to Search
IPRP + rTMS for Chronic Pain
N/A
Recruiting
Led By Jillian V Miller, PhD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Between the ages of 10-18 years
Be younger than 65 years old
Must not have
Functional neurological disorder/conversion disorder
Youth who require opioid weaning
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this outcome will be measured at day 11.
Awards & highlights
No Placebo-Only Group
Summary
This trial tests whether adding brain stimulation (rTMS) to an intensive pain rehabilitation program can help youth with severe chronic pain. The treatment uses magnetic fields to stimulate specific brain areas, aiming to reduce pain and improve mental health. The study focuses on youth who haven't responded to other treatments. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that has been used to treat various neuropsychiatric and pain conditions, including major depressive disorder, chronic pain, and epilepsy.
Who is the study for?
This trial is for young people aged 10-18 with severe chronic pain that disrupts their daily life and hasn't improved with standard pain treatments. They must understand the importance of actively managing their condition to restore function, but can't join if they have significant developmental delays, brain injuries, need opioid weaning or have untreated psychiatric illnesses.
What is being tested?
The study tests whether adding Repeated Transcranial Magnetic Stimulation (rTMS) to an Intensive Pain Rehabilitation Program (IPRP) helps reduce chronic pain in youth. The rTMS targets a specific brain area affected by chronic pain and is given daily for three weeks alongside IPRP.
What are the potential side effects?
While not specified here, common side effects of rTMS may include headache, scalp discomfort at the stimulation site, tingling or spasms of facial muscles, lightheadedness, and rare risk of seizure.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 10 and 18 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with a functional neurological disorder.
Select...
I am a young person needing help to stop using opioids.
Select...
I do not have severe medical or psychiatric conditions that would prevent rehabilitation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ this outcome will be measured at day 11.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this outcome will be measured at day 11.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Anxiety
Brain imaging
Functional disability
+7 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: rTMS + IPRPExperimental Treatment2 Interventions
25 youth aged 10-18 years with severe chronic pain will be invited to partake in the Intensive Pain Rehabilitation Program, where they will receive Repeated Transcranial Magnetic Stimulation as one of their treatment interventions.
Group II: IPRPActive Control1 Intervention
Youth within this arm will not be receiving the rTMS intervention. Rather, they will only be enrolled within the IPRP.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for chronic pain, such as neuromodulation techniques, work by targeting specific brain regions involved in pain processing and modulation. For example, Image-Guided Brain Stimulation focuses on the dorsolateral prefrontal cortex (DLPFC), a key area in pain perception and emotional regulation.
By altering the activity in the DLPFC, these treatments can reduce pain perception and improve mental health outcomes. This is crucial for chronic pain patients as it provides a non-invasive alternative to traditional pain management methods, potentially offering better long-term relief without the side effects of medications.
Effectiveness of repetitive trancranial or peripheral magnetic stimulation in neuropathic pain.Long-term experience of neuromodulation in TACs.
Effectiveness of repetitive trancranial or peripheral magnetic stimulation in neuropathic pain.Long-term experience of neuromodulation in TACs.
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
809 Previous Clinical Trials
886,364 Total Patients Enrolled
6 Trials studying Chronic Pain
611 Patients Enrolled for Chronic Pain
Jillian V Miller, PhDPrincipal InvestigatorUniversity of Calgary
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with a functional neurological disorder.I and my family agree to actively manage my recovery.I am a young person needing help to stop using opioids.I do not have severe medical or psychiatric conditions that would prevent rehabilitation.My pain severely affects my daily life and stops me from doing my usual activities.Pain treatments haven't helped me get back to my normal activities.I am between 10 and 18 years old.You have a major delay in development or a brain injury.
Research Study Groups:
This trial has the following groups:- Group 1: rTMS + IPRP
- Group 2: IPRP
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger